Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective

Aim:  To evaluate the cost utility and budget impact of second-line gefitinib for non-small cell lung cancer from a Thai payer perspective. Methods:  A Markov model with three health states (pre-progression, post-progression and death) was constructed to estimate direct medical costs and outcomes co...

Full description

Saved in:
Bibliographic Details
Main Authors: Thongprasert S., Tinmanee S., Permsuwan U.
Format: Article
Language:English
Published: 2014
Online Access:http://www.ncbi.nlm.nih.gov/pubmed/3502482
http://cmuir.cmu.ac.th/handle/6653943832/4573
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
Language: English